Advances in the management of castration-resistant prostate cancer
Docetaxel-based chemotherapy showed survival benefit and emerged as the mainstay of treatment for castration resistant prostate cancer (CRPC) in 2004. Therapeutic options have expanded rapidly since 2011. There is a broad spectrum of new agents including drugs that target the androgen axis, immunotherapy,...
Read more